Patent SG-11201809788V-A (SG)
Title: Nanoliposomal irinotecan for use in treating small cell lung cancer
Inventor: ADIWIJAYA BAMBANG
IPC: A61P35/00
Filed: 2017-05-17
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 November 2017 (23.11.2017) WIPO I PCT omit VIII Hot 0 VIII Nall °nom mil (10) International Publication Number WO 2017/199093 Al (51) International Patent Classification: A61K 31/4745 (2006.01) A61K 9/127 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/IB2017/000681 (22) International Filing Date: 17 May 2017 (17.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/337,961 18 May 2016 (18.05.2016) US 62/345,178 03 June 2016 (03.06.2016) US 62/362,735 15 July 2016 (15.07.2016) US 62/370,449 03 August 2016 (03.08.2016) US 62/394,870 15 September 2016 (15.09.2016) US 62/414,050 28 October 2016 (28.10.2016) US 62/415,821 01 November 2016 (01.11.2016) US 62/422,807 16 November 2016 (16.11.2016) US 62/433,925 14 December 2016 (14.12.2016) US 62/455,823 07 February 2017 (07.02.2017) US 62/474,661 22 March 2017 (22.03.2017) US Applicant: IPSEN BIOPHARM LTD. [GB/GB]; Ash Road, Wrexham Industrial Estate, Wrexham GB LL13 9UF (GB). Inventors: ADIWIJAYA, Bambang; 16 Brighton Street, Belmont, MA 02478 (US). FITZGERALD, Jonathan, Basil; 32 Magnolia Street, Arlington, MA 02474 (US). LEE, Helen; 120 Rindge Avenue, Apt. 100, Cambridge, MA 02140 (US). (74) Agent: CARPMAELS & RANSFORD; One Southamp- ton Row, London WC1B 5HA (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: NANOLIPOSOMAL IRINOTECAN FOR USE IN TREATING SMALL CELL LUNG CANCER FIG. 1 S N- 38 IC50( n M) 10000- 10 0 0- 100- 1 0- i- 0.1- 0.01 0 O. 0 • 0 0 0 0 0 0 00000° 0 0 0 0 0 q :3, 0 • SCLC GI Pancreas o o (57) : Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non- antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the adminis- tration of the irinotecan liposome.